Local view for "http://purl.org/linkedpolitics/eu/plenary/2016-02-02-Speech-2-834-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2016-02-02"^^xsd:date2
dcterms:Is Part Of	lp_eu:Transparency and control of clinical trials (debate)2
dcterms:Language	"en"^^xsd:language2
lpv:document identification number	"en.20160202.33.2-834-000"2
lpv:hasSubsequent	lp_eu:2016-02-02-Speech-2-835-0002
lpv:speaker	lp:Julia Reid2
lpv:spoken text	"Madam President, speaking as a pharmacologist who has been involved in clinical trials, both commercial and academic, I know how important clinical trials are in pharmaceutical development. However, the whole process is fraught with difficulty, and some of the drugs we use today, such as aspirin, would be unlikely to get approval. Regarding the track record of EU clinical trials legislation, in my experience the results to date have not been great. In the UK, the Clinical Trials Directive of 2001 made life very difficult for those of us involved in clinical trials, so much so that in my own field of small-scale phase IV trials, research was virtually curtailed. The Directive has since been replaced by the European Clinical Trial Regulation, which will be fully implemented this year. Will it be an improvement? I doubt it. Regarding transparency, UKIP strongly supports transparency in clinical trials. However, we believe that the UK Parliament and not the EU should be exclusively in charge of regulating this process."@en1
lpv:spokenAs	substitute; Committee of Inquiry into Emission Measurements in the Automotive Sector (2016-01-21--2017-04-04)3 substitute; ENVI (2014-07-01--2017-01-18)3 member; REGI (2014-07-01--2017-01-18)3
lpv:unclassifiedMetadata	"Julia Reid (EFDD )."1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph